

Attorney Docket No. BSC-216 (1002/296)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Chu et al.

SERIAL NO.:

10/017,012

GROUP NO.:

3731

FILING DATE:

December 14, 2001

EXAMINER:

Not yet assigned

TITLE:

METHODS AND APPARATUS FOR GUIDING A NEEDLE

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT CHNOLOGY CENTER R3700

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

Applicants hereby make of record the existence of U.S. Patent Application Serial No. 09/450,599, which was filed on November 30, 1999, and which claims the benefit of and priority to U.S. Patent Application Serial No. 60/131,058, which was filed on April 26, 1999, and U.S. Patent Application Serial No. 60/136,291, which was filed on May 27, 1999.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

<u>.</u>	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
	(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR

	the requisite fee under 37 C.F.R. 1.17(p), namely \$180,00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
	the requisite Statement is below, AND
	the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page <u>and</u> the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R.

 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: May **20**, 2002 Reg. No. 45,508

Tel. No.: (617) 248-7226 Fax No.: (617) 248-7100 Daniel A. Wilson

Attorney for the Applicants Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: BSC-216

APPLICANTS: Chu et al.

SERIAL NO.: 10/017,012

FILING DATE: December 14, 2001

GROUP: 3731

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	2,338,800	1/11/44	Burke			6/25/41
	A2	2,432,294	12/9/47	Dimmer			9/11/43
	A3	2,705,949	4/12/55	Silverman			8/25/53
	A4	3,349,762	10/31/67	Kapany			10/21/64
	A5	3,356,089	12/5/67	Francis			3/1/65
	A6	3,457,922	7/29/69	Ray			12/13/66
	A7	3,538,916	11/10/70	Wiles et al.			12/19/68
	A8	3,556,085	1/19/71	Takahashi			2/26/68
	A9	3,941,121	3/2/76	Olinger et al.			12/20/74
	A10	3,961,621	6/8/76	Northeved			1/24/75
	A11	4,187,848	2/12/80	Taylor			11/13/78
	A12	4,230,123	10/28/80	Hawkins, Jr.			10/31/78
	A13	4,269,192	5/26/81	Matsuo	REC	CEIVE	6/1/79
	A14	4,274,408	6/23/81	Nimrod		2 9 200	3/26/79
	A15	4,332,248	6/1/82	DeVitis	WAI	2 9 200	7/31/80
	A16	4,356,822	11/2/82	Winstead-Hall	TECHNOLO	GY CENTER	H6/47/80
	A17	4,401,124	8/30/83	Guess et al.			8/13/81
	A18	4,405,314	9/20/83	Cope			4/19/82
_	A19	4,485,815	12/4/84	Amplatz et al.			8/30/82
· · · · · · · · · · · · · · · · · · ·	A20	4,512,351	4/23/85	Pohndorf			11/19/82
	A21	4,566,438	1/28/86	Liese et al.			10/5/84
	A22	4,572,203	2/25/86	Feinstein			1/27/83
	A23	4,582,061	4/15/86	Fry			11/18/81

INFORMATION DISCLOSURE STATEMENT

OIPE

ATTORNEY DOCKET NO.: BSC-216

APPLICANTS: Chu et al.

SERIAL NO.: 10/017,012

FILING DATE: December 14, 2001

GROUP: 3731

	W.	March Carl		GROUP: 3731	
_	A5AD!	4,629,451	12/16/86	Winters et al.	9/23/85
	A25	4,639,247	1/27/87	Bokros	11/2/84
	A26 .	4,645,490	2/24/87	Rosenberg	12/18/84
	A27	4,668,222	5/26/87	Poirier	5/25/84
	A28	4,693,703	9/15/87	Rosenberg	10/17/86
	A29	4,705,510	11/10/87	Rosenberg	10/17/86
	A30	4,710,171	12/1/87	Rosenberg	6/9/86
	A31	4,718,433	1/12/88	Feinstein	12/5/85
	A32	4,750,487	6/14/88	Zanetti	11/24/86
	A33	4,787,892	11/29/88	Rosenberg	1/4/88
	A34	4,834,708	5/30/89	Pillari	3/31/87
	A35	4,869,259	9/26/89	Elkins	5/17/88
	A36	4,874,376	10/17/89	Hawkins, Jr.	4/13/87
	A37	4,886,502	12/12/89	Poirier et al.	12/9/86
	A38	4,897,081	1/30/90	Poirier et al. RECEIV	2/17/87
	A39	4,899,729	2/13/90	Gill et al. MAY 2 9 40	8/3/88
	A40	4,945,895	8/7/90	Takai et ut.	- J/20/07
*******	A41	4,977,897	12/18/90	Hurwitz TECHNOLOGY CENTER	R R3700 8/17/88
	A42	4,981,142	1/1/91	Dachman	6/24/88
	A43	4,997,424	3/5/91	Little	4/5/89
	A44	4,998,938	3/12/91	Ghajar et al.	6/9/88
	A45	5,006,115	4/9/91	McDonald	7/25/89
	A46	5,009,644	4/23/91	McDonald	7/25/89
	A47	5,047,036	9/10/91	Koutrouvelis	11/17/89
	A48	5,048,530	9/17/91	Hurwitz	4/6/90
	A49	5,059,186	10/22/91	Yamamoto et al.	3/23/89

INFORMATION DISCLOSURE STATEMENT

MAY 2 E 2022

ATTORNEY DOCKET NO.: BSC-216

APPLICANTS: Chu et al.

SERIAL NO.: 10/017,012

FILING DATE: December 14, 2001

GROUP: 3731

	TIADE			0.1001.777		
	A50	5,078,142	1/7/92	Siczek et al.		11/21/89
	A51	5,080,662	1/14/92	Paul		11/27/89
	A52	5,081,997	1/21/92	Bosley, Jr. et al.		7/20/89
	A53	5,098,397	3/24/92	Svensson et al.		9/4/90
	A54	5,104,381	4/14/92	Gresl et al.		8/30/91
	A55	5,129,911	7/14/92	Siczek et al.		3/11/91
	A56	5,135,001	8/4/92	Sinofsky et al.		12/5/90
-	A57	5,139,511	8/18/92	Gill et al.		2/13/91
	A58	5,189,690	2/23/93	Samuel		9/9/91
	A59	5,201,314	4/13/93	Bosley et al.		1/21/92
	A60	5,201,742	4/13/93	Hasson		4/16/91
	A61	5,221,269	6/22/93	Miller et al.		10/15/90
	A62	5,242,415	9/7/93	Kantrowitz et al.		8/14//92
	A63	5,242,455	9/7/93	Skeens et al.	REC	ENF [5/3/91
	A64	5,250,025	10/5/93	Sosnowski et al.		1/10/02
	A65	5,259,837	11/9/93	Van Wormer		3 9 2002 12/27/90
	A66	5,263,938	11/23/93	Orr et al.	CHNOLOG	CENTER F3 1/28/92
	A67	5,289,831	3/1/94	Bosley		4/21/92
	A68	5,308,352	5/3/94	Koutrouvelis		6/11/90
	A69	5,314,432	5/24/94	Paul		8/5/93
	A70	5,327,891	7/12/94	Rammler		7/30/92
	A71	5,383,466	1/24/95	Partika		5/14/93
	A72	5,395,317	3/7/95	Kambin	1	10/30/91
	A73	5,409,497	4/25/95	Siczek et al.		3/12/92
	A74	5,439,444	8/8/95	Andersen et al.		4/26/94
-	A75	5,489,273	2/6/96	Whitney et al.		10/7/94

INFORMATION DISCLOSURE STATEMENT

MAY 2 8 2022 (5)

ATTORNEY DOCKET NO.: BSC-216

APPLICANTS: Chu et al.

SERIAL NO.: 10/017,012

FILING DATE: December 14, 2001

GROUP: 3731

TRAD	MA		GROUP: 3/31			
A76	5,490,521	2/13/96	Davis et al.			8/16/94
A77	5,556,385	9/17/96	Andersen			12/6/94
A78	5,571,091	11/5/96	Davis et al.			9/1/95
A79	5,575,798	11/19/96	Koutrouvelis			8/22/95
A80	5,586,553	12/24/96	Halili et al.			2/16/95
A81	5,588,436	12/31/96	Narayanan et al.			10/11/95
A82	5,626,597	5/6/97	Urban et al.			2/21/95
A83	5,665,072	9/9/97	Yoon			1/11/95
A84	5,665,095	9/9/97	Jacobson			12/15/94
A85	5,670,161	9/23/97	Healy et al.			5/28/96
A86	5,676,656	10/14/97	Brimhall			7/24/96
A87	5,680,859	10/28/97	Urion et al.	;		10/11/95
A88	5,693,072	12/2/97	McIntosh			5/23/95
A89	5,725,506	3/10/98	Freeman et al.			1/5/96
A90	5,749,887	5/12/98	Heske et al.			6/1/95
A91	5,759,154	6/2/98	Hoyns		VED	12/23/96
A92	5,766,135	6/16/98	Terwilliger W	AY 2 9	2002	10/17/96
A93	5,769,795	6/23/98	Terwilliger TECHNO	LOGY CE	NTER R370	12/14/96
A94	5,779,665	7/14/98	Mastrototaro et al.			5/8/97
A95	5,792,044	8/11/98	Foley et al.			3/22/96
A96	5,799,055	8/25/98	Peshkin et al.			5/17/96
A97	5,820,554	10/13/98	Davis et al.			3/24/97
A98	5,820,600	10/13/98	Carlson et al.			5/14/96
A99	5,830,190	11/3/98	Howell			6/11/96
A100	5,833,655	11/10/98	Freed et al.			5/15/97
A101	5,843,023	12/1/98	Cecchi	· · · · · · · · · · · · · · · · · · ·		10/4/95

FORM PTO - 1449 ATTORNEY DOCKET NO.: BSC-216 INFORMATION DISCLOSURE STATEMENT APPLICANTS: Chu et al. MAY 2 8 2052 0 SERIAL NO.: 10/017,012 FILING DATE: December 14, 2001 GROUP: 3731. A102 5,851,183 12/22/98 Bucholz 10/16/95 A103 5,871,445 2/16/99 Bucholz 9/7/95 5/11/99 Foley et al. A104 5,902,231 10/24/96 A105 5,921,933 7/13/99 Sarkis et al. 8/17/98 A106 5,967,988 10/19/99 Briscoe et al. 4/8/98 A107 6,006,750 12/28/99 Field 4/30/96 1/25/00 A108 6,018,676 Davis et al. 5/18/98 A109 6,053,871 4/25/00 Cockburn 1/16/98 A110 6,106,473 8/22/00 Violante et al. 11/6/97 FOREIGN PATENT DOCUMENTS EXAM. DOCUMENT DATE COUNTRY CLASS SUB **FILING ABSTRACT ENGLISH** INIT. NUMBER CODE DATE **CLASS** ONLY LANG Y/N **B**1 96/33667 10/31/96 WO Y B2 99/00056 1/7/99 WO Y RECEIVED 1/9/97 **B**3 29519103 U1 DE **B4** 0904741 A2 3/31/99 EP Y MAY 2 9 2002 WO Y **B5** 93/10837 6/10/93 TECHNOLOGY CENTER H3/PGY **B6** 96/00044 1/4/96 WO 99/16374 4/8/99 WO **B7** Y 11/2/00 **B8** 00/64354 WO Y OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. C1 American Urological Association, Inc., Ureteral Stones Pamphlet, pp. 1-5, 7-8 (1997). Boston Scientific/Microvasive Education Center, "Percutaneous Nephrolithotomy," pp. C2 1-10 (1995). Cadeddu et al., "Stereotactic Mechanical Percutaneous Renal Access," Journal of C3 Endourology, Vol. 12, No. 2, (April 1998).

FORM PTO – 14	49	ATTORNEY DOCKET NO.: BSC-216	•
INFORMATION	DISCLOSURE STATEMENT	APPLICANTS: Chu et al.	
	OIPE	SERIAL NO.: 10/017,012	
(MAY 2 8 2022 8	FILING DATE: December 14, 2001	
\	The second	GROUP: 3731	
C4	Caronia et al., "Rettopessi per via l prolasso rettale completo," Giorn. (English Abstract.	aparoscopica: nostra esperienza nel trattamento del Chir., Vol. 20-n.6/7, pp. 311-313, (1999), with	
C5	Cook Urological, Inc., "Disposable	Two-Part Trocar Needles," 1 page, (1998).	
C6	Cook Urological, Inc., "Amplatz N	eedle Holder," 1 page, (1998).	
C7	Cook Urological, Inc., "Disposable	Long Trocar Needles," 1 page, (1998).	
C8	Cook Urological, Inc., "Disposable	Mitty-Pollack Needle Set," 1 page, (1998).	
C9	Cook Urological, Inc., "Disposable	TFE Sheath Needle," 1 page, (1998).	
C10	Cook Urological, Inc., "Cook-Cope	Loop Catheter Introduction Set," 1 page, (1998).	
C11	Cook Urological, Inc., "Percutaneo	us Entry Set," 2 pages, (1998).	
C12	Cook Urological, Inc., "NEFF Perc Band," 1 page, (1995).	eutaneous Access Sets with RB TM Design Radiopaque	
C13	Cook Urological, Inc., "NEFF Perc Hydrophilic Coating," 2 pages, (19	outaneous Access Sets with Radiopaque Band and 97).	
C14	Cook Urological, Inc., "Ultrathane Hydrophilic Coating and RB TM Rac	Amplatz Ureteral Stent Sets with Slip-Coat TM diopaque Bands," 1 page, (1996).	
C15	Cook Urological, Inc., "Ultrathane Locking Mechanism, Slip-Coat TM Introduction System," 1 page, (199		
C16	Cook Urological, Inc., "Yueh Cente	esis Disposable Catheter Needles," 1 page, (1996).	
C17	Cook Urological, Inc., "Geremia V	ertebral Biopsy Needle Set," 1 page, (1964前YOLOGY CENTER F	₹3700
C18	Engineering News, "Engineers Kee	ep Things Green," <u>Design News</u> , (Nov. 2, 1998).	
C19	Fielding, "Laparoscopic Cholecysto (1992).	ectomy," <u>Aust. N.Z. J. Surg.</u> , Vol. 62, pp. 181-187,	
C20	Gotlieb et al., "Intraperitoneal Pressures and Clinical Parameters of Total Paracentesis for Palliation of Symptomatic Ascites in Ovarian Cancer," Gynecologic Oncology, Vol. 71, pp. 381-385, (1998).		
C21	Jenkins et al., "Veres Needle in the No. 11, pp. 1383-1385, (Nov. 1983	Pleural Space," <u>Southern Medical Journal</u> , Vol. 76,).	

FORM PTO – 1449		ATTORNEY DOCKET NO.: BSC-216		
INFORMATION	ISCLOSURE STATEMENT	APPLICANTS: Chu et al.		
		SERIAL NO.: 10/017,012		
MAY 28	30.2 §	FILING DATE: December 14, 2001		
TRADEM	ARVER	GROUP: 3731		
C22 K	löckerling et al., "Die Offene Lapa	roskopie zur Vermeidung von ol.67, pp. 183-187, (1996), with English summary		
	eRoy, "Percutaneous Access," in § 10, (1996).	Smith's Textbook of Endourology, Vol. 1, pp 199-		
	mith, "Percutaneous Removal of K nknown).	Lidney Stones," Urologic Surgery, pp.116-131 (date		
C25 M	Microvasive Product Catalog; Produ	ducts for Endourology, pg. 8-2, (1996).		
C26 In	nternational Search Report for PCT	C/US99/28311, August 1, 2000, 8 pgs.		
EXAMINER		DATE CONSIDERED		

2243654-1

RECEIVE

MAY 2 9 2002

TECHNOLOGY CENTER R3700